These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Cherry N; Gilmour K; Hannaford P; Heagerty A; Khan MA; Kitchener H; McNamee R; Elstein M; Kay C; Seif M; Buckley H; Lancet; 2002 Dec 21-28; 360(9350):2001-8. PubMed ID: 12504395 [TBL] [Abstract][Full Text] [Related]
4. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Heckbert SR; Weiss NS; Koepsell TD; Lemaitre RN; Smith NL; Siscovick DS; Lin D; Psaty BM Arch Intern Med; 1997 Jun; 157(12):1330-6. PubMed ID: 9201007 [TBL] [Abstract][Full Text] [Related]
5. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat. Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153 [TBL] [Abstract][Full Text] [Related]
6. Whether the use of unopposed oestrogen following a myocardial infarction is beneficial or harmful remains unclear, and in individual women the effects may vary according to the underlying risk profile. Shapiro S Evid Based Med; 2014 Oct; 19(5):195. PubMed ID: 25009051 [No Abstract] [Full Text] [Related]
7. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ Menopause; 1999; 6(3):188-95. PubMed ID: 10486787 [TBL] [Abstract][Full Text] [Related]
8. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Psaty BM; Heckbert SR; Atkins D; Lemaitre R; Koepsell TD; Wahl PW; Siscovick DS; Wagner EH Arch Intern Med; 1994 Jun; 154(12):1333-9. PubMed ID: 8002685 [TBL] [Abstract][Full Text] [Related]
9. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Hsia J; Langer RD; Manson JE; Kuller L; Johnson KC; Hendrix SL; Pettinger M; Heckbert SR; Greep N; Crawford S; Eaton CB; Kostis JB; Caralis P; Prentice R; Arch Intern Med; 2006 Feb; 166(3):357-65. PubMed ID: 16476878 [TBL] [Abstract][Full Text] [Related]
10. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J; J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505 [TBL] [Abstract][Full Text] [Related]
11. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. West RR; Jones DA; Henderson AH Heart; 2012 Apr; 98(8):637-44. PubMed ID: 22194152 [TBL] [Abstract][Full Text] [Related]
12. Unopposed estrogen therapy and the risk of invasive breast cancer. Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578 [TBL] [Abstract][Full Text] [Related]
13. A clinical trial of estrogen-replacement therapy after ischemic stroke. Viscoli CM; Brass LM; Kernan WN; Sarrel PM; Suissa S; Horwitz RI N Engl J Med; 2001 Oct; 345(17):1243-9. PubMed ID: 11680444 [TBL] [Abstract][Full Text] [Related]
15. A multicenter study on timolol in secondary prevention after myocardial infarction. Acta Med Scand Suppl; 1983; 674():1-129. PubMed ID: 6580807 [TBL] [Abstract][Full Text] [Related]
16. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. Stampfer MJ; Colditz GA; Willett WC; Manson JE; Rosner B; Speizer FE; Hennekens CH N Engl J Med; 1991 Sep; 325(11):756-62. PubMed ID: 1870648 [TBL] [Abstract][Full Text] [Related]
17. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Fournier A; Dossus L; Mesrine S; Vilier A; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N Am J Epidemiol; 2014 Sep; 180(5):508-17. PubMed ID: 25008104 [TBL] [Abstract][Full Text] [Related]
18. The prevention of breast cancer through reduced ovarian steroid exposure. Spicer DV; Pike MC Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631 [TBL] [Abstract][Full Text] [Related]
19. A case-control study of myocardial infarction in relation to use of estrogen supplements. Rosenberg L; Palmer JR; Shapiro S Am J Epidemiol; 1993 Jan; 137(1):54-63. PubMed ID: 8434573 [TBL] [Abstract][Full Text] [Related]
20. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Heckbert SR; Kaplan RC; Weiss NS; Psaty BM; Lin D; Furberg CD; Starr JR; Anderson GD; LaCroix AZ Arch Intern Med; 2001 Jul; 161(14):1709-13. PubMed ID: 11485503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]